Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript

Kyle Qian: Hello. This is Kyle Qian leading for Sumant. So two questions. On Arimoclomol, can you compare and contrast your approach with and the potential for you to have an ADCOM that is specified with that product, given the proximity of the two estimates? And the second question is, have you had mock adcoms early on Arimoclomol and what are potential findings, and those that might have considered — you guys have considered surprising or counterintuitive?

Neil Mcfarlane: Thanks, Kyle. I’ll take the last question and I’ll hand off the question to Adrian around differentiation. To answer your question, yeah, we are thoroughly preparing for a potential advisory committee. We’ve had a number of red team, blue team exercises, preparing briefing books, multiple mock adcoms coming that we’re learning from and perfecting our craft as we move forward. So I feel like we are certainly preparing for that at this point.

Adrian Quartel: In regards to their being two targeting tests for Niemann-Pick C is great for patients. I think let’s start with that. I think it’s important to understand that Arimoclomol with its unique mode of action is really a disease modifying piece where the entire product is more symptomatic treatment, especially on this [indiscernible] disease. The differentiated mode of action and the specific clinical profile of Arimoclomol, we believe, will lead to be the foundational treatment for patients with narcolepsy. And that’s kind of where we’re looking forward to.

Operator: And this concludes the Q&A portion of today’s call. I would now like to turn the call back over to Neil McFarlane for any additional and closing remarks.

Neil Mcfarlane: Thank you, Ashley. We continue to make solid advances towards achieving our mission of building a leading patient-focused rare disease therapeutics company. As we look to our catalysts in the second half of 2024, our strategic priorities are clear, and we look forward to updating you in the future. Thanks for joining us today. Have a wonderful day.

Operator: Thank you. This does conclude today’s program. You may disconnect at any time and have a wonderful day.